Cardiovascular

Eptifibatide After PCI: Brief Infusion Is Just As Good

Anthony Fung
Anthony Fung
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as effective as longer infusions for patients receiving non-emergency percutaneous intervention. So said Anthony Fung at the first session of Late breaking Clinical Trials held at the American Heart Association’s annual meeting in Orlando. He talked with Peter Goodwin about his findings.

Similar Interviews

  • Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study
  • Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007,

  • Cardiovascular Medicine
  • Cardiologists and doctors whose patients have cardiovascular disease in any form receive up-to-date audio information via the audio journal of

  • Audio Journal of Cardiovascular Medicine 12.1, January 2006
  • Reporting from: American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas In this edition: Bryan Williams told American Heart Association attendees that

    Post a comment

    Subscribe to Audio Medica Podcast